(Q37763138)

22 August 2017

title

Systematic review of economic evaluations of Alzheimer's disease medications (English)

1 reference

22 August 2017

0 references

1 reference

Mark Oremus

1

1 reference

22 August 2017

publication date

1 June 2008

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

22 August 2017

published in

1 reference

22 August 2017

volume

8

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

273-289

1 reference

Worldwide prevalence and incidence of dementia

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Effective pharmacologic management of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Donepezil for the Treatment of Mild to Moderate Alzheimer’s Disease in France: The Economic Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Economic evaluation of donepezil treatment for Alzheimer's disease in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Economic impact of introducing propentofylline for the treatment of dementia in Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

The economic impact of the tacrine in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Economic evaluation of donepezil in moderate to severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

An economic evaluation of donepezil in the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

The cost of dementia in Denmark: the Odense Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

AD2000: design and conclusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Review of outcome measurement instruments in Alzheimer's disease drug trials: introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Utility-based Quality of Life measures in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

A hybrid qualitative method for pretesting questionnaires: the example of a questionnaire to caregivers of Alzheimer disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

Physicians' efficacy requirements for prescribing medications to persons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.3.273

21 January 2018

Identifiers

DOI

10.1586/14737167.8.3.273

1 reference

22 August 2017

1 reference